bioRxivNeurosciencePreprint
Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice
Shih-Wei Chou, Meredith A MortbergiD, Kimberly MarleniD, David S. Ojala, Toufan Parman, Michael Howard, Kendrick DeSouza-Lenz, Yuan LianiD, Mohadeseh MehrabianiD, Matthew R. Tiffany, Annemarie Ledeboer, Patrick Dunn, Jing Hu, Kenia GuzmaniD, Nikita Kamath, Morgan Cass, Samantha Graffam, Li XuiD, Vanessa LaversenneiD, Taylor L CorridoniD, Alaric Falcon, Garrett Lew, Satria P. SajuthiiD, Lei ZhangiD, Giulia CisbaniiD, , Bryan ZeitleriD
Abstract
Prion disease is a rapidly progressing and invariably fatal neurodegenerative disorder with no approved treatment. The disease is caused by the self-templated misfolding of the prion protein (PrP) into toxic species, ultimately leading to neurodegeneration and death. We evaluated a novel epigenetic regulation approach using Zinc Finger Repressors (ZFRs) to ablate PrP expression at the transcriptional level. When delivered using adeno-associated virus (AAV), ZFRs potently and specifically reduced prion mRNA expression by >95% in vitro and to near undetectable levels within single neurons in vivo. In wildtype mice, ZFRs stably lowered neuronal PrP expression throughout the central nervous system for at least 17 months. In mice inoculated with misfolded PrP, AAV-ZFRs given at either early or late disease stages profoundly extended lifespan, significantly reduced PrP in the brain, and improved an array of molecular, histological, biomarker, and behavioral readouts. Finally, we delivered a ZFR targeting the human prion gene (PRNP) to cynomolgus monkeys using a novel blood-brain-barrier penetrant AAV capsid. Extensive bulk and single-cell assessments revealed widespread ZFR expression and PRNP repression in all 35 brain regions assessed, providing the first demonstration of epigenetic regulation across the nonhuman primate neuraxis following a single intravenous (IV) dose. These results highlight the potential of a one-time IV administered ZFR treatment for prion disease and other neurological disorders.
- organism: non-human primate
- organism: mouse
- assay: bulk RNA-seq
- assay: scRNA-seq
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: experimental assay
- Citations
- 14
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Prevention of prion disease symptoms in mice with deep PrP lowering
Juliana E Gentile, Jonathan E. Farley, … Eric Vallabh Minikel·bioRxiv·Oct 24, 2026
- Prion protein lowering is a disease-modifying therapy across prion strains, disease stages, and endpoints
Eric Vallabh Minikel, Hien Tran Zhao, … Sonia M. Vallabh·Nucleic Acids ResearchPeer-reviewed·Jul 13, 2020
- Therapeutic window for treatment of prion disease defined by timed depletion of Prion protein
Barry Matthew Bradford, Alison Marshall, … Jean C. Manson·bioRxiv·Nov 18, 2024
- A self-complementary recombinant adeno-associated virus vector coding for an anchorless prion protein carrying the G127V mutation extends survival in a rodent prion disease model
Thomas Zerbes, Claire E. Verkuyl, … Gerold Schmitt‐Ulms·PLOS PathogensPeer-reviewed·Aug 4, 2026
- Divalent siRNA for prion disease
Juliana E Gentile, Taylor L Corridon, … Sonia M. Vallabh·Nucleic Acids ResearchPeer-reviewed·Mar 19, 2026
- Leveraging the dominant-negative effect of the kuru-protective G127Vprion protein variant as a novel therapeutic strategy
Jean R.P. Gatdula, Nadia A. Mirza-Romero, … David A. Harris·Neurobiology of DiseasePeer-reviewed·Jun 29, 2026